New employee warrants at $240.52 issued by Ascendis Pharma (ASND)

Rhea-AI Filing Summary

Ascendis Pharma A/S reports that its board granted 22,480 warrants to certain employees under its Articles of Association. Each warrant allows the holder to buy one ordinary share at an exercise price of US $240.52, matching the ADS closing price on the grant date.

Twenty-five percent of the warrants vest one year after the grant, with the remaining 75% vesting monthly over the following three years, subject to continued service and possible earlier vesting on certain exit events. After this grant, warrants to subscribe for an additional 1,644,153 shares remain available for future grants.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Warrant Grants

On March 10, 2026, the Company’s board of directors granted an aggregate of 22,480 warrants to certain employees of the Company (the “Warrants”) under the terms of Appendix 1a to the Company’s Articles of Association. In connection with the grant of these Warrants, the Company amended its Articles of Association to provide for the grant of these Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company and has an exercise price equal to US $240.52 per share, the closing price of the American Depositary Shares (“ADS”) representing the Company’s ordinary shares as reported on the date of grant. Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest on the one year anniversary of the date of grant and the remaining 75% will vest at a rate of 1/36th per month from one year after the date of grant, subject to continued service.

After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 1,644,153 shares of the Company remain available for future grant by the Company’s board of directors pursuant to the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: March 11, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

FAQ

What did Ascendis Pharma (ASND) announce in this Form 6-K?

Ascendis Pharma reported granting 22,480 employee warrants under its Articles of Association. Each warrant gives the right to buy one ordinary share and is intended as equity-based compensation, aligning employees’ interests with long-term shareholder value.

How many warrants did Ascendis Pharma (ASND) grant and to whom?

The company granted an aggregate of 22,480 warrants to certain employees. These equity awards are designed to reward and retain staff, providing potential upside if the company’s share price performs well over time.

What is the exercise price of the new Ascendis Pharma (ASND) warrants?

Each warrant has an exercise price of US $240.52 per share, equal to the closing price of Ascendis Pharma’s American Depositary Shares on the March 10, 2026 grant date, linking employee incentives to the prevailing market valuation.

How do the Ascendis Pharma (ASND) warrants vest over time?

Twenty-five percent of the warrants vest one year after grant, with the remaining 75% vesting in equal monthly installments over the next 36 months. Vesting requires continued service and may accelerate on specified exit events outlined in the Articles of Association.

How many additional warrants can Ascendis Pharma (ASND) still grant?

After this grant, Ascendis Pharma has warrants remaining to subscribe for an additional 1,644,153 shares. This reserve provides capacity for future equity-based incentives authorized by the board under the company’s Articles of Association.

Is this Ascendis Pharma (ASND) Form 6-K incorporated into existing registrations?

Yes. The report is incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements, meaning the information becomes legally part of those previously filed offering documents for securities issuance.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 1.2 MB